Search Follow us

cannabis

1 - 6 of 6
Sort by: popularity | newest
Page  of 1
CannTrust Holdings

Capitalising on medical cannabis opportunity

QuickView | Pharmaceutical & healthcare | 16 May 2018

CannTrust is a leading producer of high-quality, standardised, pesticide-free medical cannabis (MC) products for chronic healthcare applications such as the treatment of pain, anxiety, depression, nausea and other conditions. Recent formalised MC regulation in Canada led to strong MC demand and CannTrust is increasing its production capacity accordingly.

Intec Pharma

AP-CDB/THC performs in Phase I

Update | Pharmaceutical & healthcare | 29 Aug 2017

Intec Pharma announced on 3 August 2017 that it had completed the Phase I clinical trial of AP-CBD/THC in 21 healthy volunteers. AP-CBD/THC is a formulation of cannabidiol and tetrahydrocannabinol using Intec’s proprietary accordion pill technology. The trial compared its safety, tolerability, and pharmacokinetics to the buccal cannabis extract, Sativex. AP-CBD/THC showed improved exposure, time at peak, and metabolism compared to Sativex without any safety or tolerability concerns.

Thin Film Electronics

Tapping the booming medical marijuana market

Flash note | Technology | 12 Jun 2017

Thin Film Electronics (Thinfilm) has announced an agreement with California's leading medical marijuana supplier, Caliva, to incorporate Thinfilm NFC solutions into its packaging. Caliva sells a wide range of products including 21 different strains of cannabis with different potencies and cultivation practices, as well as a range of over 130 cannabis-containing foods and ancillary equipment. Caliva is looking to enhance the shopper experience and provide more consistency, transparency and accessibility towards the cannabis space, as well as boosting marketing via offers and events. In 2016, California became the fifth US state to legalise recreational use of marijuana. Public sales of cannabis from stores are expected to start in 2018, which should lead to a further substantial increase in Caliva's sales.

Therapix Biosciences

Cannabinoids for underserved diseases

QuickView | Pharmaceutical & healthcare | 07 Jun 2017

Therapix recently underwent an IPO on NASDAQ in the US of 2.3m ADS (worth $13.8m) to finance the clinical development of cannabinoid products. The lead clinical program, THX-TS01, is a combination of THC, the primary active ingredient in cannabis, and palmitoylethanolamide, a molecule generally regarded as safe, which is approved for use as a health supplement in some parts of Europe and Canada. THX-TS01 is currently in Phase II trials testing its potential for treating Tourette's in adults. Therapix also has a preclinical program, dubbed THX-ULD01, seeking to treat mild cognitive impairment (MCI) using ultra-low dose THC, which is scheduled to begin Phase I trials in late Q217 or Q317. Both programs should qualify for a 505(b)(2) pathway to streamline their approval processes.

Intec Pharma

Progress across ongoing and new clinical trials

Update | Pharmaceutical & healthcare | 22 May 2017

Intec Pharma has made significant progress, both with its current development programme and in new directions. The company is in a Phase III clinical trial of an accordion pill (AP) formulation of carbidopa and levodopa (AP-CDLD), and announced that it has reduced the target trial size to 328 patients (from 460) based on feedback from experts, and expects to be fully enrolled by Q417. Additionally, the company announced in March 2017 that it has started a Phase I trial expected to complete in Q317 of an AP formulation with cannabidiol and tetrahydrocannabinol (AP-CBD/THC), the two primary cannabinoids in Cannabis sativa.

GW Pharmaceuticals

Pot luck

Outlook | Pharmaceutical & healthcare | 28 Sep 2009

GW Pharmaceuticals offers an investment geared to the near-term success of Sativex, a therapeutic extract of the cannabis plant. Sativex is on the brink of receiving EU regulatory approval, triggering milestone revenue and its first meaningful sales. GW’s expertise in plant genetics and ability to operate under UK Home Office licence could make it the first company legally to derive a significant financial benefit from the cannabis plant.